Literature DB >> 11323426

Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene.

M Giampuzzi1, G Botti, M Cilli, R Gusmano, A Borel, P Sommer, A Di Donato.   

Abstract

Several investigations have suggested a putative tumor suppressor role for lysyl oxidase because it is down-regulated in many human and oncogene-induced tumors. To address this issue we down-regulated the enzyme in normal rat kidney fibroblasts by stable transfection of its cDNA in an antisense orientation. The selected clones revealed an absence of lysyl oxidase and dramatic phenotypic changes, interpretable as signs of transformation. The antisense lysyl oxidase clones showed, indeed, loose attachment to the plate and anchorage-independent growth and were highly tumorigenic in nude mice. Moreover, we found an impaired response of the PDGF and IGF-1 receptors to their ligands. In particular, the transformed cells showed a down-regulation of both PDGF receptors and expressed the 105-kDa isoform of the IGF-1 beta receptor, which was not present in the normal control cells. The lack of response to PDGF-BB has been described as a feature of many ras-transformed phenotypes. Therefore, we looked at the status of the p21(ras). Indeed, we found a significantly higher level of active p21(ras) both during steady-state growth and prolonged starvation. Our data reveal new evidence for a tumor suppressor activity of lysyl oxidase, highlighting its particular role in controlling Ras activation and growth factor dependence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323426     DOI: 10.1074/jbc.M101695200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer.

Authors:  Shulamit Sebban; Regina Golan-Gerstl; Rotem Karni; Olga Vaksman; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2012-07-18       Impact factor: 5.150

2.  A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression.

Authors:  Héctor Peinado; Maria Del Carmen Iglesias-de la Cruz; David Olmeda; Katalin Csiszar; Keith S K Fong; Sonia Vega; Maria Angela Nieto; Amparo Cano; Francisco Portillo
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

3.  Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.

Authors:  Juan Liu; Wei Ping; Yukun Zu; Wei Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 4.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

5.  Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

Authors:  Sébastien Jeay; Stefania Pianetti; Herbert M Kagan; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Newbold; Kefah Mokbel
Journal:  J Carcinog       Date:  2010-11-12

7.  A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Authors:  Chengyin Min; Ziyang Yu; Kathrin H Kirsch; Yingshe Zhao; Siddharth R Vora; Philip C Trackman; Douglas B Spicer; Lynn Rosenberg; Julie R Palmer; Gail E Sonenshein
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

8.  Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities.

Authors:  Shulamit Sebban; Ben Davidson; Reuven Reich
Journal:  Virchows Arch       Date:  2008-11-18       Impact factor: 4.064

Review 9.  Hypoxia and the extracellular matrix: drivers of tumour metastasis.

Authors:  Daniele M Gilkes; Gregg L Semenza; Denis Wirtz
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

Review 10.  The rationale for targeting the LOX family in cancer.

Authors:  Holly E Barker; Thomas R Cox; Janine T Erler
Journal:  Nat Rev Cancer       Date:  2012-07-19       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.